Implementation of a seamless phase 2/3 study design in the setting of an emergent infectious disease pandemic: Lessons learned from the ACTIV-2 platform COVID-19 treatment trial

By sjmartinez • March 28, 2025

Giganti MJ, Chew KW, Moser C, Eron JJ, Pinilla M, Li JZ, Ritz J, Javan AC, Wohl DA, Daar ES, Currier JS, Smith DM, Hughes MD; ACTIV-2/A5401 Study Team. Implementation of a seamless phase 2/3 study design in the setting of an emergent infectious disease pandemic: Lessons learned from the ACTIV-2 platform COVID-19 treatment trial. Contemp Clin Trials. 2025 Mar 25:107887. doi: 10.1016/j.cct.2025.107887. Epub ahead of print. PMID: 40147543.

Tags: Bayesian, covid-19, Go/No-Go, Graduation, Harbor UCLA, Infectious Diseases, Phase 2/3, Platform, Publications, Seamless

Interleukin-6 Inhibition with Ziltivekimab for Atherosclerotic Disease

Ridker PM, Lincoff AM, Marx N, Navar AM, Sattar N, Tuttle KR, Budoff M, Böttcher M, Cavender MA, Choudhury RP, Cornel JH, Gajos G, Komuro[...]

Development and Validation of a Pre-COPD Score to Predict Incident COPD

Çolak Y, Bhatt SP, Kinney GL, Casaburi R, Nordestgaard BG, Vestbo J, Lange P, Afzal S. Development and Validation of a Pre-COPD Score to Predict[...]

Advancements in Artificial Intelligence for Enhanced Diagnosis and Prognosis in Cardiac CT: a Comprehensive Review and Future Perspectives

Adabifirouzjaei F, Budoff M, Nomeli M. Advancements in Artificial Intelligence for Enhanced Diagnosis and Prognosis in Cardiac CT: a Comprehensive Review and Future Perspectives. Curr[...]